AZN:NYSE
AstraZeneca PLC (US)
$160.17
arrow_downward
-1.56%(-2.53) 1D
Sep 8, 3:14:34 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
$163.96
High
$163.96
Low
$159.40
Mkt. cap
248.93B
Avg. vol.
3.91M
Volume
3.43M
Dividend
2.01%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
23.94
52-wk high
$212.71
52-wk low
$72.90
EPS
$6.69
Beta
0.28
Shares outstanding
1.55B
No. of employees
96K
Open
$163.96
High
$163.96
Low
$159.40
Mkt. cap
248.93B
Avg. vol.
3.91M
Volume
3.43M
Dividend
2.01%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
23.94
52-wk high
$212.71
52-wk low
$72.90
EPS
$6.69
Beta
0.28
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
TradingView
·
58 minutes ago
AZN: Tozorakimab's broad efficacy in COPD supports major growth potential and FDA priority review
AD HOC NEWS
·
1 hour ago
AstraZeneca stock dips as new cancer and lung trials reshape the pipeline
Yahoo Finance
·
2 hours ago
AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test
Los Angeles Times
·
3 hours ago
AstraZeneca’s breast cancer pill gets approval from the FDA
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com